Meta AnalysisID 4164
东莨菪碱治疗重性抑郁障碍：系统评价与Meta分析的研究方案
CRD42022351926
Is scopolamine(I) effective and safe in the treatment of major depressive disorder(P)? Is scopolamine as useful or more useful than conventional therapy(C)?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 4164
- Evidence Id
- 12722
- Core Evidence Id
- 12722
- Source Meta Analysis Id
- 4123
- Herb2 Meta Analysis Id
- HBMA004123
- Crd Id
- CRD42022351926
- Title
- Scopolamine in the treatment of major depressive disorder: protocol of a systematic review and meta-analysis
- Review Question
- Is scopolamine(I) effective and safe in the treatment of major depressive disorder(P)? Is scopolamine as useful or more useful than conventional therapy(C)?
- Study Type Included
- This study will include randomised controlled trials (RCTs) without restriction of publication type.
- Condition Being Studied
- Depression is a common mental illness with high rates of disability, suicide and recurrence. The Global Burden of Disease Study 2013 reported that depression ranks first in the global burden of mental illness. At present, depression is primarily treated with antidepressants, while it still have some adverse effects, and may increase the suicidal tendency. In recent years, scopolamine，as a newly discovered rapid antidepressant, has been studied in the treatment of depression. However, its efficacy and safety have not yet reached a definitive conclusion. Therefore, this research is designed to evaluate the efficacy and safety of the scopolamine for depression using the method of systematic review and meta-analysis.
- Participant
- The participants should meet the diagnosis of major depressive disorder in accordance with Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) and/or the International Classification of Diseases (ICD), regardless of their degree and possible complications. There is no limitation in their genders, races and regions.
- Animal
- Human Disease Modelled
- Intervention
- All available dose and treatment modality of scopolamine performed in MDD will be considered as interventions.
- Comparator Control
- The control group received placebo treatment.
- Main Outcome
- 1. Reduction in the severity of depressive symptoms measured by self-rating or examiner-rating scales. 2. Safety evaluated by the percentage of patients who withdrew from the trials because of adverse events and the severity.
- Outcome Measure
- Additional Outcome
- Response rate.
- Study Method
- Intervention, Meta-analysis, Systematic review
- Keyword
- Depression; Depressive Disorder, Major; Humans; Meta-Analysis as Topic; Scopolamine Derivatives; Systematic Reviews as Topic
- Contact
- Qing Yang [email protected]
- Organisational Affiliation
- Guangzhou University of Chinese Medicine
- Funding Source
- 1.Key-Area Research and Development Program of Guangdong Province-Key Special Project of Lingnan Traditional Chinese Medicine Modernization, 2020B1111100007, The clinical and cognitive neurological mechanism research of Shugan Tiaoshen integrated acupuncture and moxibustion in the treatment of moderate depression , 2020/01-2024/12; 2.Guangdong Academy of Traditional Chinese Medicine, YN2019ML13, Research on the neural mechanism of functional reset of brain executive control system in subthreshold depression population, 2019/09-2022/08; 3.National Natural Science Foundation of China, 82074522, Explore the mechanism of the rapid antidepressant function of acupuncture based on the theory of M1-Ach receptors in prefrontal lobe regulating glutamate/γ-aminobutyric acid balance to mediate synaptic plasticity, 2021/01-2024/12; 4.Natural Science Foundation of Guangdong Province, 2019A1515012043, The rapid antidepressant mechanism of acupuncture by antagonizing GABA interneuron receptors to regulate synaptic plasticity, 2019/10-2022/09.
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2022-08-07
- Registration Date
- 2022-08-17
- Anticipated Start Date
- 2022-08-10
- Anticipated Completion Date
- 2022-12-10
- Title Cn
- 东莨菪碱治疗重性抑郁障碍：系统评价与Meta分析的研究方案
- Title En
- Scopolamine in the treatment of major depressive disorder: protocol of a systematic review and meta-analysis
- Bilingual Status
- complete